Fisher & Paykel Healthcare Corporation Limited Ord Shares
FPH.NZXHealth Care
Fisher & Paykel Healthcare is a global leader in medical devices and systems for use in respiratory care and acute care, and in the treatment of obstructive sleep apnea. The company has a consistent growth strategy to provide an expanding range of innovative medical devices which can help to improve care and outcomes for patients in an increasing range of applications. Its products are sold to hospitals and healthcare facilities around the world through direct sales offices operations and a network of distributors that sell to hospitals, homecare providers and other manufacturers of medical devices. Formerly Fisher & Paykel Industries, Fisher & Paykel Healthcare arose from the separation of the major trading businesses of Fisher & Paykel Industries into Appliances and Healthcare in November 2001. The company's securities are listed in both New Zealand and Australia.
Market Data
$37.290
-0.0%$21.9B
46.7x
$0.798
1.58%
+0.1%
Latest Earnings
FPH reports strong revenue and profit growth for FY26
26 May 2026
Fisher & Paykel Healthcare delivered strong FY26 results with total operating revenue up 14% to NZ$2.31 billion and net profit after tax up 24% to NZ$468.5 million (28% in constant currency). The Hospital segment was the standout performer with 18% revenue growth to $1.51 billion, while Homecare grew 8% to $802.7 million. The company provided upbeat FY27 guidance with revenue of $2.45–$2.57 billion and NPAT of $500–$550 million, and lifted the full-year dividend 22% to 52.0 cents per share. Key points: Revenue grew 14% to NZ$2.31 billion (12% in constant currency), with Hospital segment up 18% to NZ$1.51 billion and Homecare up 8% to NZ$802.7 million; NPAT grew 24% to NZ$468.5 million (28% in constant currency), with operating margin expanding 235 bps to 27.6%; Gross margin improved 80 bps to 63.7% (122 bps in constant currency) driven by continuous improvement initiatives, despite ~90 bps headwind from US tariffs on NZ-sourced hospital products
Recent Announcements
FPH reports strong revenue and profit growth for FY26
Fisher & Paykel Healthcare delivered strong FY26 results with total operating revenue up 14% to NZ$2.31 billion and net profit after tax up 24% to NZ$468.5 million (28% in constant currency). The Hospital segment was the standout performer with 18% revenue growth to $1.51 billion, while Homecare grew 8% to $802.7 million. The company provided upbeat FY27 guidance with revenue of $2.45–$2.57 billion and NPAT of $500–$550 million, and lifted the full-year dividend 22% to 52.0 cents per share. Key points: Revenue grew 14% to NZ$2.31 billion (12% in constant currency), with Hospital segment up 18% to NZ$1.51 billion and Homecare up 8% to NZ$802.7 million; NPAT grew 24% to NZ$468.5 million (28% in constant currency), with operating margin expanding 235 bps to 27.6%; Gross margin improved 80 bps to 63.7% (122 bps in constant currency) driven by continuous improvement initiatives, despite ~90 bps headwind from US tariffs on NZ-sourced hospital products
SPH Notice - The Vanguard Group, Inc.
The Vanguard Group, Inc disclosed a change in substantial holding (5.001%).
SPH Notice - Pinnacle Investment Management Group Limited
Pinnacle Investment Management Group Limited disclosed a change in substantial holding (5.0145%).
FPH to announce full year results on 26 May 2026
Fisher & Paykel Healthcare Corporation Limited announced it will release its full year financial results for the year ended 31 March 2026 on Tuesday, 26 May 2026 at 9:00am NZST, followed by a conference call at 10:00am NZST with webcast access available.
Ongoing Disclosure Notice - Ordinary Shares
Justin Peter Callahan, Vice President - Sales & Marketing at Fisher & Paykel Healthcare Corporation Limited, acquired 129 ordinary shares on 1 April 2026 at NZD 31.2811 per share through the Employee Stock Purchase Plan, increasing his holding from 220,738 to 220,867 shares.
Capital Change Notice - North America ESPP
Fisher & Paykel Healthcare Corporation Limited issued 12,584 ordinary shares on 1 April 2026 at NZ$31.2811 per share to employees participating in the company's North American Employee Stock Purchase Plan, representing 0.00214% of total issued shares.
SPH Notice - BlackRock, Inc. and related bodies corporate
BlackRock, Inc. and related bodies corporate changed substantial holding from 6.577% to 7.616%.
SPH Notice - Pinnacle Investment Management Group Limited
Pinnacle Investment Management Group Limited changed substantial holding from 4.9754% to 5.0487%.
FPH updates FY26 revenue and earnings guidance
Fisher & Paykel Healthcare upgraded its FY26 guidance with revenue now expected to be approximately $2.30 billion (up from $2.17-2.27B range) and net profit after tax of $450-470 million (up from $410-460M range), driven by good growth across Hospital products and margin improvements. The company noted potential upside from US tariff refunds following a Supreme Court ruling but did not incorporate this into guidance. Management highlighted pleasing progress in changing clinical practice and operational efficiency gains contributing to improved margins. Key points: Revenue guidance upgraded to $2.30B from previous range of $2.17-2.27B; NPAT guidance upgraded to $450-470M from previous range of $410-460M; Good growth continuing across full range of Hospital products in second half
Initial Disclosure Notice - Ordinary Shares
Anna Valerie Curzon disclosed her initial shareholding as a newly appointed Director of Fisher & Paykel Healthcare Corporation Limited, holding 600 ordinary shares with beneficial interest.
Get real-time alerts for FPH
Receive AI-powered earnings summaries and instant notifications when Fisher & Paykel Healthcare Corporation Limited Ord Shares releases results.
Register Free